Cost savings with nefazodone in treating depression

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 1, 2002, Pages 48-51

  Hales, Robert E ^a   Hilty, Donald M ^a   Brunson, Gregory H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANXIOLYTIC AGENT; FLUOXETINE; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY NEUROSIS; COST CONTROL; DECISION MAKING; DEPRESSION; DRUG CHOICE; ELECTROENCEPHALOGRAM; HUMAN; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; COST SAVINGS; DEPRESSIVE DISORDER; DRUG COSTS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP DISORDERS; TRIAZOLES;

EID: 0036194022     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Economic appraisal of antidepressant pharmacotherapy: Critical review of the literature and future directions
2. A critical review of published economic modeling studies in depression
3. The treatment of depression in UK general practice: Selective serotonin reuptake inhibitors and tricyclic antidepressants compared
4. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: A cost-effectiveness study of nefazodone
5. Incorporating utility-based quality of life assessments in clinical trials: 2 Examples
6. Methodology for measuring health-state preferences, 3: Population and context effects
7. Modelling the cost effectiveness of antidepressant treatment in primary care
8. Economic analysis of treating depression with nefazodone v imipramine
9. What price depression? The cost of depression and the cost effectiveness of pharmacological treatment
10. Long-term treatment of depression with nefazodone
11. Cost-effectiveness of newer anti-depressants compared with tricyclic antidepressants in managed care settings
12. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients
13. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: A double-blind, 8-week clinical trial
14. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder
15. The effects of nefazodone on sleep in depressed patients and healthy controls
16. A double-blind comparison of nefazodone, imipramine, and placebo in major depression
17. Response of anxiety and agitation symptoms during nefazodone treatment of major depression
18. Retrospective chart review comparing nefazodone to 3 selective serotonin reuptake inhibitors for treatment of depression with agitation or anxiety
19. Nefazodone therapy and concomitant anxiolytic and sedative/hypnotic drug therapy in patients with depression
20. Economic aspects of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy and their combination for the treatment of chronic major depression